Nick Leschly at JPM20 (Jeff Rumans)
September 12, 2023 07:36 AM EDTUpdated 11:43 AM
People
Cell/Gene Tx

Up­dat­ed: 2sev­en­ty lays off 40% of staff, prunes CAR-T pipeline as Nick Leschly steps down as CEO

Amber Tong

Katherine Lewin

News Reporter

With an ear­ly-stage CAR-T un­der clin­i­cal hold, 2sev­en­ty bio is slash­ing its head­count by 40% and cap­ping spend­ing on some pipeline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times